Dupilumab (COPD) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 5 of the dossier assessment Dupilumab (COPD) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dupilumab (COPD ) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-79 Version: 1.0 Status: 28 Oct 2024 DOI: 10.60584/A24-79_en Extract of dossier assessment A24-79 Version 1.0 Dupilumab ( COPD) 28 Oct 2024 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dupilumab (COPD) – Benefit assessment according
Dupilumab (Dupixent) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * Français SearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs and health
Dupilumab (prurigo nodularis) ' Addendum to Project A23-24 1 Translation of addendum A23-82 Dupilumab (Prurigo nodularis) – Addendum zum Projekt A23-24 (Dossierbewertung). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dupilumab (prurigo nodularis ) Addendum to Project A23-24 (dossier assessment)1 ADDENDUM Project: A23-82 Version: 1.0 Status: 14 September 2023 Addendum A23-82 Version 1.0 Dupilumab – Addendum to Project A23-24 14 September 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dupilumab (prurigo nodularis) – Addendum to Project A23
Dupilumab (prurigo nodularis) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Dupilumab (Prurigo nodularis) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dupilumab (prurigo nodularis) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-24 Version: 1.0 Status: 28 June 2023 Extract of dossier assessment A23-24 Version 1.0 Dupilumab ( prurigo nodularis) 28 June 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dupilumab
Dupilumab (atopic dermatitis, 6 months to 5 years) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Dupilumab (atopische Dermatitis, 6 Monate bis 5 Jahre) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dupilumab (atopic dermatitis, 6 months to 5 years) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-25 Version: 1.0 Status: 28 June 2023 Extract of dossier assessment A23-25 Version 1.0 Dupilumab ( atopic dermatitis, 6 months to 5 years) 28 June 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing
Dupilumab (eosinophilic oesophagitis) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Dupilumab (eosinophile Ösophagitis) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dupilumab (eosinophilic oesophagitis) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-23 Version: 1.0 Status: 28 June 2023 Extract of dossier assessment A23-23 Version 1.0 Dupilumab ( eosinophilic oesophagitis) 28 June 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care
Dupilumab (Dupixent) Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information on drugs and health products Search for clinical information on drugs
Dupilumab (Dupixent) Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information on drugs and health products Search for clinical information on drugs
Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis Published: 2 January 2024 Driving Better Decision-Making in Healthcare Page 1 Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis Technology Guidance from the MOH Drug Advisory Committee Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has are recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024. Abrocitinib should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with moderate-to-severe atopic dermatitis. MAF assistance does not apply to any formulations or strengths of baricitinib, upadacitinib or dupilumab
Dupilumab (Dupixent) - severe asthma Final Appraisal Recommendation Advice number: 1522 – September 2022 Dupilumab (Dupixent®) 200 mg and 300 mg solution for injection in pre-filled syringe or pre-filled pen Submission by Sanofi Recommendation of the All Wales Medicines Strategy Group Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales. Dupilumab (Dupixent®) is licensed in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. Dupilumab (Dupixent®) is restricted
Dupilumab (Dupixent) - eosinophilic esophagitis Published 10 June 2024 Statement of advice SMC2682 dupilumab solution for injection in pre-filled pen and syringe (Dupixent®) Sanofi 10 May 2024 ADVICE: in the absence of a submission from the holder of the marketing authorisation dupilumab (Dupixent®) is not recommended for use within NHSScotland. Indication under review: treatment of eosinophilic
Dupilumab (Dupixent) - prurigo nodularis 1 Published 12 February 2024 1 SMC2598 dupilumab 300 mg solution for injection in pre-filled syringe or pre-filled pen (Dupixent®) Sanofi 12 January 2024 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland . The advice is summarised as follows: ADVICE: following a full submission assessed under the orphan equivalent medicine process. dupilumab (Dupixent®) is accepted for use within NHSScotland. Indication under review: for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy. In two double-blind, randomised, phase III studies, dupilumab treatment
Dupilumab for treating bullous pemphigoid Dupilumab for treating bullous pemphigoid - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world leading Horizon Scanning Facility The NIHR Innovation Observatory is a world leading health and care innovation scanning centre, providing data-driven insights to foster innovation * Our Networks * Our Stakeholders * Our Work with NICE * Health & Life Sciences Ecosystem * Engage * Industry * Public Involvement * Capacity Building * Events * News * Resources * Contact 27 March 2024 Dupilumab for treating bullous pemphigoidDupilumab is currently in phase II/III development for adult patients with bullous pemphigoid (BP). Dupilumab is currently in phase II/III development for adult